Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
BackgroundAnthracyclines are associated with cardiotoxic effects. Cardiovascular biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may precede and predict the development of left ventricular impairment. The aim of this study was to assess: (1) longitudinal change...
Main Authors: | Geeta Gulati, Siri L. Heck, Helge Røsjø, Anne H. Ree, Pavel Hoffmann, Tor‐Arne Hagve, Jon Norseth, Berit Gravdehaug, Kjetil Steine, Jürgen Geisler, Torbjørn Omland |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-11-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.117.006513 |
Similar Items
-
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
by: A Mecinaj, et al.
Published: (2021-09-01) -
The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity
by: Ahmed Ayuna, et al.
Published: (2020-09-01) -
Diagnostic Thresholds for Pre–Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population: Data From the ACE 1950 Study
by: Peder L. Myhre, et al.
Published: (2021-06-01) -
Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study
by: Høiseth Arne, et al.
Published: (2012-07-01) -
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
by: Muthiah Vaduganathan, MD, MPH, et al.
Published: (2019-09-01)